ClinicalTrials.gg
CompletedNCT00285077Updated Dec 23, 2008

Long-Term Safety Extension With SR57667B in Patients With Alzheimer's Disease

A Phase 2 interventional study of SR57667B in Alzheimer Disease, sponsored by Sanofi. Completed at 7 sites in 7 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2008-12-23.

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
390
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Alzheimer Disease by Sanofi — 1 open to participants now, 1 under way, none of them phase 3. Alzheimer Disease · Sanofi.

Enrollment
4th of 11
390 · median 162
Started
2004
the only one that year
Phase 2
6 of 11
1 open now
Registered
3rd of 11
by date

Among the 11 studies in Alzheimer Disease by Sanofi, this one is the 4th largest by enrollment, is the only one that started in 2004, is one of 6 in phase 2, and was the 3rd registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

1 of the 11 studies in Alzheimer Disease by Sanofi is open now, in 7 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Alzheimer Disease by Sanofi, or all of them as a file.
02

Study summary

The primary objective is to assess the long term safety/tolerability of 4 mg/day of SR57667B in comparison to placebo in patients with mild-to-moderate Alzheimer's Disease (AD).

A secondary objective is to describe the long term progression of Alzheimer's symptoms in patients treated by 4 mg/day of SR57667B.

Read the detailed description

Multinational, multicenter, randomized, parallel-group, double-blind, phase II study

03

Conditions studied

  • Alzheimer Disease

Browse trials for

Keywords

  • Alzheimer disease
  • nerve growth factors
  • Clinical Trial
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who have participated in Study EFC5286 and completed the study.
  • Patient, identified caregiver and, if applicable, patient surrogate (primary relative, legal guardian, medical proxy) have given their informed written consent and are capable of following study procedures specifically for this LTS5283 extension.

Exclusion criteria

Exclusion Criteria:

  • Females who are pregnant or breast-feeding.
  • Females of child bearing potential (premenopausal female biologically capable of becoming pregnant) must have a confirmed negative serum b-HCG pregnancy test at the screening visit,and must use an acceptable method of .
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
390 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Adverse events recorded quarterly.

Secondary outcomes

  1. ADAS-cog, CDR, MMSE, CGIC, ADCS-ADL, NPI measured at baseline and at 2,6,9 and 12 months.

07

Study locations

7 sites
  • Sanofi-Aventis Administrative Office
    Laval, Canada
  • Sanofi-Aventis Administrative Office
    Horslholm, Denmark
  • Sanofi-Aventis Administrative Office
    Helsinki, Finland
  • Sanofi-Aventis Administrative Office
    Paris, France
  • Sanofi-Aventis Administrative Office
    Berlin, Germany
  • Sanofi-Aventis Administrative Office
    Midrand, South Africa
  • Sanofi-Aventis Administrative Office
    Bromma, Sweden
08

References and documents

Related links

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2004, a primary completion of Nov 2006 and a completion of Nov 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 31, 2006
First posted
Feb 1, 2006
Start
Mar 2004
Primary completionActual
Nov 2006
CompletionActual
Nov 2006
Last update
Dec 23, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 23, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00285077
Lead sponsor
Sanofi
First posted
Feb 1, 2006
Start date
Mar 2004
Primary completion
Nov 2006
Completion
Nov 2006
Last update
Dec 23, 2008

Study contacts

Serge GAUTHIER, MD
study chair · Scientific Advisory Committee
Jean-Marc ORGOGOZO, MD
study chair · Scientific Advisory Committee
Philip SCHELTENS, MD
study chair · Scientific Advisory Committee
Bengt WINBLAD, MD
study chair · Scientific Advisory Committee
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Paliroden

Start the discussion